Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-10
2006-10-10
Saeed, Kamal (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S211000
Reexamination Certificate
active
07119108
ABSTRACT:
Novel cannabimimetic pyrazole derivatives are presented which have preferentially high affinities for both of the cannabinoid CB1 or CB2 receptor sites. The improved receptor affinity makes these analogs useful as experimental tools for cannabinoid receptor studies as well as clinically useful agents in individuals and animals for treatment of memory deficits associated with aging or neurological diseases, as anti-obesity agents, as medications for schizophrenia and treatment of septic shock syndrome.
REFERENCES:
patent: 3041343 (1962-06-01), Jucker et al.
patent: 3465024 (1969-09-01), Brownstein et al.
patent: 3573327 (1971-03-01), Miyano
patent: 3577458 (1971-05-01), Brownstein et al.
patent: 3656906 (1972-04-01), Bullock
patent: 3838131 (1974-09-01), Gauthier et al.
patent: 3886184 (1975-05-01), Matsumoto et al.
patent: 3897306 (1975-07-01), Vidic
patent: 3915996 (1975-10-01), Wright
patent: 3928598 (1975-12-01), Archer
patent: 3944673 (1976-03-01), Archer
patent: 3946029 (1976-03-01), Descamps et al.
patent: 3953603 (1976-04-01), Archer
patent: 4036857 (1977-07-01), Razdan et al.
patent: 4054582 (1977-10-01), Blanchard et al.
patent: 4087545 (1978-05-01), Archer et al.
patent: 4087546 (1978-05-01), Archer et al.
patent: 4087547 (1978-05-01), Archer et al.
patent: 4088777 (1978-05-01), Archer et al.
patent: 4102902 (1978-07-01), Archer et al.
patent: 4152450 (1979-05-01), Day et al.
patent: 4171315 (1979-10-01), Ryan et al.
patent: 4176233 (1979-11-01), Archer et al.
patent: 4179517 (1979-12-01), Mechoulam
patent: 4188495 (1980-02-01), Althuis et al.
patent: 4208351 (1980-06-01), Archer et al.
patent: 4278603 (1981-07-01), Thakkar et al.
patent: 4282248 (1981-08-01), Mechoulam et al.
patent: 4382943 (1983-05-01), Winter et al.
patent: 4395560 (1983-07-01), Ryan
patent: 4497827 (1985-02-01), Nelson
patent: 4550214 (1985-10-01), Mehta
patent: 4758597 (1988-07-01), Martin et al.
patent: 4812457 (1989-03-01), Narumiya
patent: 4876276 (1989-10-01), Mechoulam
patent: 4885295 (1989-12-01), Bell et al.
patent: 5053548 (1991-10-01), Tanaka et al.
patent: 5068234 (1991-11-01), D'Ambra et al.
patent: 5147876 (1992-09-01), Mizuchi et al.
patent: 5223510 (1993-06-01), Gubin et al.
patent: 5284867 (1994-02-01), Kloog
patent: 5324737 (1994-06-01), D'Ambra et al.
patent: 5434295 (1995-07-01), Mechoulam et al.
patent: 5440052 (1995-08-01), Makriyannis et al.
patent: 5462960 (1995-10-01), Barth et al.
patent: 5489580 (1996-02-01), Makriyannis et al.
patent: 5521215 (1996-05-01), Mechoulam
patent: 5532237 (1996-07-01), Gallant et al.
patent: 5538993 (1996-07-01), Mechoulam
patent: 5576436 (1996-11-01), McCabe et al.
patent: 5605906 (1997-02-01), Lau
patent: 5607933 (1997-03-01), D'Ambra et al.
patent: 5618955 (1997-04-01), Mechoulam et al.
patent: 5624941 (1997-04-01), Barth et al.
patent: 5631297 (1997-05-01), Pate et al.
patent: 5635530 (1997-06-01), Mechoulam
patent: 5688825 (1997-11-01), Makriyannis et al.
patent: 5744459 (1998-04-01), Makriyannis et al.
patent: 5747524 (1998-05-01), Cullinan et al.
patent: 5804601 (1998-09-01), Kato et al.
patent: 5817651 (1998-10-01), D'Ambra et al.
patent: 5872148 (1999-02-01), Makriyannis et al.
patent: 5874459 (1999-02-01), Makriyannis et al.
patent: 5925628 (1999-07-01), Lee et al.
patent: 5925768 (1999-07-01), Barth et al.
patent: 5932610 (1999-08-01), Shohami et al.
patent: 5939429 (1999-08-01), Kunos et al.
patent: 5948777 (1999-09-01), Bender et al.
patent: 6013648 (2000-01-01), Rinaldi et al.
patent: 6028084 (2000-02-01), Barth et al.
patent: 6096740 (2000-08-01), Mechoulam
patent: 6166066 (2000-12-01), Makriyannis et al.
patent: 6284788 (2001-09-01), Mittendorf et al.
patent: 6391909 (2002-05-01), Makriyannis et al.
patent: 6579900 (2003-06-01), Makriyannis et al.
patent: 6610737 (2003-08-01), Garzon et al.
patent: 2002/0119972 (2002-08-01), Leftheris et al.
patent: 2002/0173528 (2002-11-01), Fride et al.
patent: 2003/0120094 (2003-06-01), Makriyannis et al.
patent: 2003/0149082 (2003-08-01), Makriyannis et al.
patent: 2004/0077649 (2004-04-01), Makriyannis et al.
patent: 2004/0077851 (2004-04-01), Makriyannis et al.
patent: 2004/0087590 (2004-05-01), Makriyannis et al.
patent: 0276732 (1988-08-01), None
patent: 0444451 (1991-09-01), None
patent: 0471609 (1993-06-01), None
patent: 0576357 (1993-12-01), None
patent: 0737671 (1996-10-01), None
patent: 0860168 (2001-09-01), None
patent: 2240003 (1975-05-01), None
patent: 2735774 (2000-01-01), None
patent: 2027021 (1980-02-01), None
patent: 1995-113228 (1999-09-01), None
patent: 57098228 (1982-06-01), None
patent: 2304080 (1990-12-01), None
patent: WO 94/12466 (1994-06-01), None
patent: WO 97/00860 (1997-01-01), None
patent: WO 97/21682 (1997-06-01), None
patent: WO 99/57106 (1999-11-01), None
patent: WO 99/57107 (1999-11-01), None
patent: WO 99/64389 (1999-12-01), None
patent: WO 00/32200 (2000-06-01), None
patent: WO 01/28329 (2001-04-01), None
patent: WO 01/28497 (2001-04-01), None
patent: WO 01/28498 (2001-04-01), None
patent: WO 01/28557 (2001-04-01), None
patent: WO 01/32169 (2001-05-01), None
patent: WO 01/58869 (2001-08-01), None
patent: WO 02/058636 (2002-08-01), None
patent: WO 02/060447 (2002-08-01), None
patent: WO 03/005960 (2003-01-01), None
patent: WO 03/020217 (2003-03-01), None
patent: WO 03/035005 (2003-05-01), None
patent: WO 03/063758 (2003-08-01), None
patent: WO 03/064359 (2003-08-01), None
European Search Report; European Patent Application No. EP 00 98 2694; (Four (4) Pages.
Azido-and Isothiocyanato-Substituted Aryl Pyrazoles Bind Covalently to the CB1Cannabinoid Receptor and Impair Signal Transduction; Allyn C. Howlett et al; pp. 2174-2181.
U.S. Appl. No. 09/600,786, filed Nov. 24, 1999, Makriyannis et al.
U.S. Appl. No. 09/701,989, filed Jun. 9, 1999, Makriyannis et al.
U.S. Appl. No. 10/110,830, filed Oct. 18, 2000, Makriyannis et al.
U.S. Appl. No. 10/110,812, filed Oct. 18, 2000, Makriyannis et al.
U.S. Appl. No. 10/110,862, filed Oct. 18, 2000, Makriyannis et al.
U.S. Appl. No. 10/111,059, filed Oct. 18, 2000, Makriyannis et al.
U.S. Appl. No. 10/483,482, filed Jul. 11, 2002, Makriyannis et al.
U.S. Appl. No. 10/493,093, filed Oct. 28, 2002, Makriyannis et al.
U.S. Appl. No. 10/,647,544, filed Aug. 25, 2003, Makriyannis et al.
U.S. Appl. No. 10/790,498, filed Mar. 1, 2004, Makriyannis et al.
Abadji V., Lin S., Taha G., Griffin G., Stevenson L.A., Pertwee R.G., Makriyannis A.; “(R)-Methanadamide: a chiral novel anandamide possessing higher potency and metabolic stability”; J. Med. Chem.; 37(12); 1889-1893; 1994; CODEN; JMCMAR; ISSN: 0022-2623; XP002040932.
Alo, B.I.; Kandil, A.; Patil, P. A.; Sharp, M. J; Siddiqui, M. A.; and Snieckus, V. Sequential Directed Ortho Metalation-Boronic Acid Cross-Coupling Reactions. A general Regiospecific Route to Oxygenerated Dibenzo[b,d]pyran-6-ones Related to Ellagic Acid, J. Org. Chem. 1991, 56, 3763-3768.
*** Archer et al; “cannabinoids, synthesis approaches to 9-ketocannabinoids.”;J. Org. Chem.; vol. 42; No. 13; 2277-2284; (1977).
Arnone M., Maruani J., Chaperon P, et al, Selective inhibition of sucrose and ethanol intake by SR141716, an antagonist of central cannabinoid (CB1) receptors, Psychopharmacal, (1997) 132, 104-106. (abstract only).
Barnett-Norris et al; “Exploration of biologically relevant conformations of anandamide, . . . ”; J. Med. Chem.; vol. 41; 4861-4872; 1998.
Beak, P.; and Brown, R A., The Tertiary Amide as an Effective Director of Ortho Lithiation, J. Org. Chem. 1982, 47, 34-36.
Belgaonkar et al; “synthesius of isocoumarins”; Indian J. Chem; vol. 13; No. 4; 336-338; 1975 (abstract only).
Beltramo M., Stella N., Calignano A., Lin S. Y., Makriyannis A., Piomelli D; “Functional Role Of High-Affinity Anandamide Transport, as Revealed By Selective Inhibition”; Science; vol. 277; 1094-1097; 1997.
Beltramo M., Stella N., Calignano A., Lin S. Y., Makriyannis A., Piomelli D; “Identification and Functional Role of High Affinity Anandamide Transport”; The Neurosciences Institute (1 page).
Berdyshev EV, Cannabinoid receptors and the regulat
Liu Qian
Makriyannis Alexandros
Alix Yale & Ristas, LLP
Saeed Kamal
University of Connecticut
LandOfFree
Pyrazole derivatives as cannabinoid receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazole derivatives as cannabinoid receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazole derivatives as cannabinoid receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3702917